Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2001

01-11-2001

An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer

Authors: H Bonnefoi, L Biganzoli, T Cufer, L Mauriac, A Hamilton, P Schaefer, M Piccart

Published in: Breast Cancer Research and Treatment | Issue 1/2001

Login to get access
Metadata
Title
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
Authors
H Bonnefoi
L Biganzoli
T Cufer
L Mauriac
A Hamilton
P Schaefer
M Piccart
Publication date
01-11-2001
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2001
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1012530607649

Other articles of this Issue 1/2001

Breast Cancer Research and Treatment 1/2001 Go to the issue

OriginalPaper

Allelic loss of chromosome 3p24 correlates with tumor progression rather than with retinoic acid receptor β2 expression in breast carcinoma

OriginalPaper

Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells

OriginalPaper

Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline

OriginalPaper

Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer

OriginalPaper

Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer

OriginalPaper

Role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits